Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into mid-2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FULC:
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
- Fulcrum Therapeutics Appoints Chief Financial Officer
- Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
- Fulcrum Therapeutics signs exclusive license agreement with CAMP4 Therapeutics
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)